Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226

Active Not RecruitingPhase 3

Sponsor: Janssen Research & Development, LLC

Conditions: Plaque Psoriasis

Interventions: JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab

Countries: United States, Argentina, Australia, Austria, Belgium, Canada, Denmark, Germany

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Eligibility overview

Sex: ALL

Age: 12 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

* Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
* Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
* Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)
Locations (160)
  • Birmingham, Alabama, United States
  • Encinitas, California, United States
  • Encino, California, United States
  • Fountain Valley, California, United States
  • Oceanside, California, United States
  • Rocklin, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Santa Ana, California, United States
  • Sylmar, California, United States
  • Farmington, Connecticut, United States
  • Miami, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Tampa, Florida, United States
  • Alpharetta, Georgia, United States
  • Skokie, Illinois, United States
  • Plainfield, Indiana, United States
  • Iowa City, Iowa, United States
  • Bowling Green, Kentucky, United States
  • Boston, Massachusetts, United States
  • Brighton, Massachusetts, United States
  • Caledonia, Michigan, United States
  • Detroit, Michigan, United States
  • Fort Gratiot, Michigan, United States
  • Troy, Michigan, United States
  • New Brighton, Minnesota, United States
  • Kirksville, Missouri, United States
  • Saint Joseph, Missouri, United States
  • New York, New York, United States
  • + 130 more on CT.gov